Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and tes ...

Core Insights - Context Therapeutics Inc. has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025, succeeding Dr. Karen Smith who will remain on the Board of Directors [1][4] - Dr. Chagin has over a decade of experience in clinical development and regulatory strategy for T cell therapies, having previously held senior roles at Adaptimmune and Tmunity [2][3] - The company is focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [7] Leadership Transition - Dr. Chagin's appointment is seen as pivotal for the company's growth, bringing valuable insights from her experience in moving programs from early development to approval [4] - Dr. Smith's interim leadership has been acknowledged, highlighting her contributions during the transition [4] Stock Option Grant - As part of her employment, Dr. Chagin will receive a non-qualified stock option award of 153,000 shares, with the exercise price based on the closing price of the company's stock on her start date [5][6] - The stock option will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments [6] Company Overview - Context Therapeutics is a biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies for solid tumors [7]

Core Insights - Context Therapeutics Inc. is advancing its clinical pipeline with two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials, with initial clinical data expected in 2026 [2][3] - The company reported cash and cash equivalents of $89.4 million as of March 31, 2025, which is projected to fund operations into 2027 [2][10] - Research and development expenses increased to $3.5 million in Q1 2025 from $2.0 million in Q1 2024, primarily due to costs associated with CT-202 and CT-95 [5][9] Financial Performance - For the first quarter of 2025, Context reported a net loss of $4.6 million, compared to a loss of $3.7 million in the same period of 2024 [6][9] - General and administrative expenses rose to $2.1 million in Q1 2025 from $1.9 million in Q1 2024, driven by increased personnel costs [5][9] - Other income for Q1 2025 was approximately $1.0 million, up from $0.2 million in Q1 2024, mainly due to higher interest income [5][9] Upcoming Developments - The company plans to file an Investigational New Drug (IND) application for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in mid-2026 [2][3] - Context will present at the Citizens Life Sciences Conference on May 8, 2025, and participate in one-on-one meetings at the D. Boral Capital Inaugural Global Conference on May 14, 2025 [5][4]

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a m ...